Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy

NCT ID: NCT03106350

Last Updated: 2017-04-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

103 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-01

Study Completion Date

2017-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

EORTC-QLQ-30 questionnaire filled in by participants 6 times

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

EORTC-QLQ-30 questionnaire filled in by participants 6 times

* 1st before receive radiotherapy
* 2nd after receive radiotherapy
* 3th 1 month after receive radiotherapy
* 4th 3 month after receive radiotherapy
* 5th 6 month after receive radiotherapy
* 6th 1 year after receive radiotherapy

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Quality of Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

questionnaire

EORTC-QLQ-30 questionnaire

Questionnaire

Intervention Type OTHER

The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Questionnaire

The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EORTC-QLQ-30 Questionnaire

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* good consciousness
* ability to understand and provide information
* no hearing impairment
* Eastern Cooperative Oncology Group performance level of 0 to 2

Exclusion Criteria

* prior radiotherapy
Minimum Eligible Age

20 Years

Maximum Eligible Age

80 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chulabhorn Cancer Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Saengrawee Thanthong

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Saengrawee Thanthong, M.N.S

Role: PRINCIPAL_INVESTIGATOR

Chulabhorn Hospital

References

Explore related publications, articles, or registry entries linked to this study.

Jim HS, Andrykowski MA, Munster PN, Jacobsen PB. Physical symptoms/side effects during breast cancer treatment predict posttreatment distress. Ann Behav Med. 2007 Oct;34(2):200-8. doi: 10.1007/BF02872674.

Reference Type BACKGROUND
PMID: 17927558 (View on PubMed)

Manning-Walsh J. Social support as a mediator between symptom distress and quality of life in women with breast cancer. J Obstet Gynecol Neonatal Nurs. 2005 Jul-Aug;34(4):482-93. doi: 10.1177/0884217505278310.

Reference Type BACKGROUND
PMID: 16020416 (View on PubMed)

Williams SA, Schreier AM. The effect of education in managing side effects in women receiving chemotherapy for treatment of breast cancer. Oncol Nurs Forum. 2004 Jan-Feb;31(1):E16-23. doi: 10.1188/04.ONF.E16-E23.

Reference Type BACKGROUND
PMID: 14722602 (View on PubMed)

Sahin ZA, Tan M. Quality of Life and Symptom Experience of Breast Cancer Patients Undergoing Chemotherapy. Holist Nurs Pract. 2016 Jul-Aug;30(4):193-200. doi: 10.1097/HNP.0000000000000157.

Reference Type BACKGROUND
PMID: 27309408 (View on PubMed)

Deshields TL, Potter P, Olsen S, Liu J. The persistence of symptom burden: symptom experience and quality of life of cancer patients across one year. Support Care Cancer. 2014 Apr;22(4):1089-96. doi: 10.1007/s00520-013-2049-3. Epub 2013 Dec 3.

Reference Type BACKGROUND
PMID: 24292095 (View on PubMed)

Roiland RA, Heidrich SM. Symptom clusters and quality of life in older adult breast cancer survivors. Oncol Nurs Forum. 2011 Nov;38(6):672-80. doi: 10.1188/11.ONF.672-680.

Reference Type BACKGROUND
PMID: 22037330 (View on PubMed)

Liang SY, Chao TC, Tseng LM, Tsay SL, Lin KC, Tung HH. Symptom-Management Self-efficacy Mediates the Effects of Symptom Distress on the Quality of Life Among Taiwanese Oncology Outpatients With Breast Cancer. Cancer Nurs. 2016 Jan-Feb;39(1):67-73. doi: 10.1097/NCC.0000000000000244.

Reference Type BACKGROUND
PMID: 25730592 (View on PubMed)

Wu HS, Harden JK. Symptom burden and quality of life in survivorship: a review of the literature. Cancer Nurs. 2015 Jan-Feb;38(1):E29-54. doi: 10.1097/NCC.0000000000000135.

Reference Type BACKGROUND
PMID: 24831042 (View on PubMed)

Reed E, Kossler I, Hawthorn J. Quality of life assessments in advanced breast cancer: should there be more consistency? Eur J Cancer Care (Engl). 2012 Sep;21(5):565-80. doi: 10.1111/j.1365-2354.2012.01370.x. Epub 2012 Jun 4.

Reference Type BACKGROUND
PMID: 22672416 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx

2.1. Globocan 2012: Estimate Cancer Incidence, Mortality and Prevalence Worldwide in 2012

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

13/2557

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improving Care After Chemotherapy
NCT01944137 COMPLETED NA